Brokerage firm Jefferies Maintains its rating on Aclaris Therapeutics Inc(NASDAQ:ACRS). In a research note issued to the investors, the brokerage major Raises the price-target to $31.00 per share. The shares have been rated Buy. The rating by Jefferies was issued on Sep 19, 2016.
In a different note, On Aug 12, 2016, Jefferies said it Maintains its rating on Aclaris Therapeutics Inc. In the research note, the firm Raises the price-target to $20.00 per share. The shares have been rated ‘Buy’ by the firm.
Aclaris Therapeutics Inc(ACRS) last announced its earnings results on Aug 11, 2016 for Fiscal Year 2016 and Q2.Earnings per share were $-0.62. Analysts had estimated an EPS of $-0.62.
Several Insider Transactions has been reported to the SEC. On Aug 29, 2016, Kamil Ali-jackson (Chief Legal Officer) sold 3,738 shares at $20.35 per share price.Also, On Oct 13, 2015, Albert Cha (director) purchased 454,545 shares at $11.00 per share price.On Oct 13, 2015, Anand Mehra (director 10% owner) purchased 409,090 shares at $11.00 per share price, according to the Form-4 filing with the securities and exchange commission.
Aclaris Therapeutics Inc. is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying developing and commercializing differentiated therapies in dermatology. The Company’s drug candidate A-101 is being developed as an in-office treatment for seborrheic keratosis a non-cancerous skin tumor as well as for other cutaneous indications such as common warts. In addition the Company is engaged in developing a portfolio of Janus Kinase (JAK) inhibitor compounds for the treatment of alopecia areata and other dermatological conditions. The Company’s products A-201 and A-301 are indicated for the treatment of alopecia areata. The Company’s A-101 product is entering Phase III clinical trials for the treatment of seborrheic keratosis and Phase II clinical trials for the treatment of common warts. The Company’s A-201 and A-301 products are in pre- clinical stage.